Glaukos Co. (NYSE:GKOS) Position Raised by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. boosted its position in Glaukos Co. (NYSE:GKOS - Free Report) by 1.4% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 650,697 shares of the medical instruments supplier's stock after acquiring an additional 8,936 shares during the quarter. Charles Schwab Investment Management Inc. owned 1.18% of Glaukos worth $97,566,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in GKOS. Amalgamated Bank grew its holdings in shares of Glaukos by 4.5% during the 3rd quarter. Amalgamated Bank now owns 15,926 shares of the medical instruments supplier's stock worth $2,075,000 after purchasing an additional 679 shares during the period. Crossmark Global Holdings Inc. grew its stake in Glaukos by 15.8% during the third quarter. Crossmark Global Holdings Inc. now owns 4,051 shares of the medical instruments supplier's stock worth $527,000 after buying an additional 554 shares during the period. Versor Investments LP acquired a new stake in shares of Glaukos in the third quarter worth $457,000. WCM Investment Management LLC raised its stake in shares of Glaukos by 45.7% in the 3rd quarter. WCM Investment Management LLC now owns 99,155 shares of the medical instruments supplier's stock valued at $12,721,000 after acquiring an additional 31,084 shares during the period. Finally, Victory Capital Management Inc. raised its stake in shares of Glaukos by 421.8% in the 3rd quarter. Victory Capital Management Inc. now owns 79,211 shares of the medical instruments supplier's stock valued at $10,320,000 after acquiring an additional 64,031 shares during the period. 99.04% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

Glaukos Stock Up 5.5 %

NYSE GKOS traded up $5.34 during trading hours on Wednesday, reaching $103.13. 1,403,487 shares of the company traded hands, compared to its average volume of 855,302. The stock has a market capitalization of $5.83 billion, a PE ratio of -35.93 and a beta of 0.99. The company has a current ratio of 5.54, a quick ratio of 4.71 and a debt-to-equity ratio of 0.19. Glaukos Co. has a 12 month low of $84.08 and a 12 month high of $163.71. The company has a 50 day moving average of $143.84 and a two-hundred day moving average of $138.41.

Glaukos (NYSE:GKOS - Get Free Report) last issued its quarterly earnings results on Thursday, February 20th. The medical instruments supplier reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.02). The company had revenue of $105.50 million for the quarter, compared to the consensus estimate of $100.72 million. Glaukos had a negative return on equity of 16.53% and a negative net margin of 39.04%. As a group, equities analysts expect that Glaukos Co. will post -1.08 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on GKOS. Truist Financial increased their price target on Glaukos from $152.00 to $185.00 and gave the company a "buy" rating in a report on Wednesday, December 18th. Piper Sandler reiterated an "overweight" rating and issued a $180.00 target price (up previously from $140.00) on shares of Glaukos in a research note on Monday, January 27th. Citigroup upgraded Glaukos from a "neutral" rating to a "buy" rating and raised their target price for the company from $132.00 to $162.00 in a report on Wednesday, December 11th. UBS Group began coverage on Glaukos in a report on Friday, December 6th. They issued a "buy" rating and a $182.00 price target for the company. Finally, BTIG Research increased their price objective on shares of Glaukos from $140.00 to $149.00 and gave the company a "buy" rating in a research report on Tuesday, November 26th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $163.25.

Insider Activity at Glaukos

In other news, insider Tomas Navratil sold 3,416 shares of the firm's stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $147.14, for a total value of $502,630.24. Following the transaction, the insider now directly owns 72,437 shares in the company, valued at approximately $10,658,380.18. This trade represents a 4.50 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Gilbert H. Kliman sold 10,000 shares of Glaukos stock in a transaction dated Friday, December 20th. The shares were sold at an average price of $150.28, for a total transaction of $1,502,800.00. Following the completion of the transaction, the director now directly owns 32,336 shares of the company's stock, valued at $4,859,454.08. This trade represents a 23.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 16,744 shares of company stock valued at $2,504,131. Corporate insiders own 6.40% of the company's stock.

Glaukos Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.